The Biotech Startups Podcast

The Biotech Startups Podcast

Excedr
Country USA
Language EN
Episodes 266
Latest 19.11.2026

The Biotech Startups Podcast by Excedr features weekly conversations with founders, scientists, and investors driving biotech innovation. Host Jon Chee dives into the challenges of building biotech startups, from pre-seed to IPO. New episodes are released every Monday and Thursday.

Episodes

  • 🧬 A Sales Job That Never Felt Like Selling | Ilya Burkov (2/4)
    🧬 A Sales Job That Never Felt Like Selling | Ilya Burkov (2/4) 19.11.2026 25m
    Ilya Burkov is Global Head of Scientific AI & Healthcare at Nebius. PhD done, Ilya has to decide what comes next. He wants to stay close to healthcare, but he's done pretending the bench is the only road. The first role he finds is business development at a medical diagnostics company, which is where the conversation gets honest about the word scientists flinch at: sales. Jon admits it feels icky coming out of a lab. Ilya's pushback is simple: clinicians are data-driven, so if your reagents genuinely improve their results, you're showing people what they've been missing. A year in the job and...
  • 🧬 The Disease Signal Shows Up Before Symptoms | Ilya Burkov (1/4)
    🧬 The Disease Signal Shows Up Before Symptoms | Ilya Burkov (1/4) 16.11.2026 34m
    Ilya Burkov is Global Head of Scientific AI & Healthcare at Nebius. Ilya's parents had one rule for every childhood ambition, astronaut, fireman, chef: get a foundation first, then choose. He took it seriously. Sports year round, science projects, Scouts trips, and around ten A levels, because biology, law, electronics, and further maths all seemed worth knowing. Where did the road really start? A hospital, he says, where he volunteered as a teenager, brought tea to long-term patients, and kept noticing that homes had Dysons while wards had old fans.
  • 🧬 The $500 Lab That Started a Company | James Evans Rerelease (3/3)
    🧬 The $500 Lab That Started a Company | James Evans Rerelease (3/3) 12.11.2026 17m
    You need a lab. James Evans found hoods for $500, looked at JLABS in San Diego, and walked away because the price and the fit were wrong. A decade later the company still hasn't taken the predetermined fundraising staircase. He went for a walk before the taping, told his wife those other podcast guests were rock stars, and landed on the only label that fit: scrappy.
  • 🧬 Science Is Twenty Percent of the Problem | James Evans Rerelease (2/3)
    🧬 Science Is Twenty Percent of the Problem | James Evans Rerelease (2/3) 09.11.2026 21m
    Paul Matsudaira took a job in Singapore, and James Evans did not wake up one morning craving entrepreneurship. He left MIT's Whitehead Institute, bounced through venture-backed biotechs, and got a baptism of fire defending data in rooms that wanted a fight. One San Diego client won a contract, and that was enough to plant PhenoVista in California with a year of runway and no paying customers yet.
  • 🧬 Kickflips and Bacterial Pellets Built a Founder | James Evans Rerelease (1/3)
    🧬 Kickflips and Bacterial Pellets Built a Founder | James Evans Rerelease (1/3) 05.11.2026 27m
    James Evans calls himself a late starter. Childhood in the UK was skateboarding and video games, not science kits. His dad was an engineer and his mom was a nurse, which only looks like a straight line if you draw it afterwards. Science wasn't in the house. Soccer was mainstream. Skateboarding was not, and that counterculture stubbornness is the part he still recognizes in company building.
  • 🧬 Almost $100 Million. No Venture. | Steve Visco Rerelease (3/3)
    🧬 Almost $100 Million. No Venture. | Steve Visco Rerelease (3/3) 02.11.2026 36m
    Steve Visco grew PolyPlus Battery Company on government contracts instead of a stack of tiny SBIRs. Lawrence Berkeley had already taught him how to write large proposals. The danger, he says, is chasing money that pulls the company off its North Star. Once you sign, you cannot renegotiate the work. You get reports, audits, and no BMWs in the parking lot. ARPA-E will kill a grant that stalls. His grant-writing rule is the same as a venture pitch: why should anyone care, who is on the team, and don't ask for too little.
  • 🧬 “We're Going to Burn Your Company to the Ground” | Steve Visco Rerelease (2/3)
    🧬 “We're Going to Burn Your Company to the Ground” | Steve Visco Rerelease (2/3) 29.10.2026 34m
    Steve Visco's spinout found its first CEO in the audience. Rudolph Hurwich had already built Dymo, cashed out, and was hunting for another shot at something big. He offered to raise the angel round and take the job when Steve said he wasn't ready. The founding four were faculty: Steve, Lutgard De Jonghe at Berkeley, Michel Armand in Montreal and Grenoble, and Meilin Liu at Georgia Tech.
  • 🧬 He Chose Santa Barbara Over Icebergs | Steve Visco Rerelease (1/3)
    🧬 He Chose Santa Barbara Over Icebergs | Steve Visco Rerelease (1/3) 26.10.2026 35m
    Steve Visco was an introverted kid with a microscope, pond water, and books on Louis Pasteur and Jonas Salk. School science lagged years behind what he was already doing at home. Literature almost pulled him into writing instead of the lab. He still treats writing as a leadership skill, because too many scientists cannot explain why their work matters. A high-school rock band got him used to being watched. That comfort later showed up in grant pitches.
  • If It's Getting More Complex, You're Going the Wrong Way | Scott Chetham (4/4)
    If It's Getting More Complex, You're Going the Wrong Way | Scott Chetham (4/4) 22.10.2026 40m
    Scott Chetham explains why he left Google and Verily to tackle the unglamorous planning work that slows clinical development. He recounts sketching the company in Costa Rica, raising a pre-napkin-stage round with Polaris, finding an early customer, and adapting when COVID-19 disrupted pharma economics.
  • The Clinical Trial Bottleneck Is Not Discovery | Scott Chetham (3/4)
    The Clinical Trial Bottleneck Is Not Discovery | Scott Chetham (3/4) 19.10.2026 30m
    The conversation then moves to the decisions that determine whether a trial succeeds: what to measure, whom to enroll, and when to measure it. Scott uses Amgen's osteoporosis strategy to show how a focused endpoint and staged market entry can outperform an attempt to capture everything at once.
  • Knowledge Is Now a Commodity | Scott Chetham (2/4)
    Knowledge Is Now a Commodity | Scott Chetham (2/4) 15.10.2026 34m
    The conversation then turns to scaling teams through uncertainty. Scott shares how company growth creates organizational whiplash, why founders often underestimate the need for change management, and how leaders can stay close to what employees and customers are actually experiencing.
  • The Hard Part Starts After the Demo | Scott Chetham (1/4)
    The Hard Part Starts After the Demo | Scott Chetham (1/4) 12.10.2026 35m
    Scott Chetham traces the influences that shaped his path into life sciences, from growing up on Australia's Gold Coast and watching his parents build careers through work and education to studying the intersection of engineering and medicine. He shares how a combined degree, early exposure to hospitals, and an unusual appetite for difficult problems pushed him toward biomedical research.
  • Letting Go Is a Leadership Skill | Leslie Loveless (4/4)
    Letting Go Is a Leadership Skill | Leslie Loveless (4/4) 08.10.2026 37m
    As Slone Partners grew beyond its original five-person team, Leslie Loveless had to confront one of the hardest parts of leadership: letting go. She talks about delegation, resisting the urge to rewrite everyone else's work, and learning that a different approach can still be the right approach.
  • The Employee Number Five Leap That Built a Relationship Business | Leslie Loveless (3/4)
    The Employee Number Five Leap That Built a Relationship Business | Leslie Loveless (3/4) 05.10.2026 33m
    Leslie Loveless joined Slone Partners after a major personal transition, leaving a large healthcare company to become employee number five at a small recruiting firm. She hadn't worked in recruiting before, and at the time, she didn't fully appreciate how big the leap would be.
  • Winning President's Club with Zero Sales Experience | Leslie Loveless (2/4)
    Winning President's Club with Zero Sales Experience | Leslie Loveless (2/4) 01.10.2026 27m
    Leslie Loveless leaves the classroom for pharmaceutical sales in 1999, a coveted industry at the time. She describes the culture shock of moving from a school building into a territory-based role, where her days meant driving between providers, managing her own schedule, and learning to sell one to one.
  • How Teaching High School Prepares You to Run a Company | Leslie Loveless (1/4)
    How Teaching High School Prepares You to Run a Company | Leslie Loveless (1/4) 28.09.2026 34m
    Leslie Loveless starts at the beginning: growing up in a close-knit Indiana family, watching her father build a career as a pharmacist, and learning early that education mattered even if the eventual career path was left up to her.
  • The Catalyst Mindset Behind a Lean Biotech | Örn Almarsson (4/4)
    The Catalyst Mindset Behind a Lean Biotech | Örn Almarsson (4/4) 24.09.2026 25m
    He then turns to company building at Axelyf: in vivo cell reprogramming for solid tumors, modular lipid nanoparticles, AI-informed discovery, external partners, and a deliberately lean operating model. The conversation closes with the mentors, expectations, and leadership philosophy shaping his next chapter.
  • The Delivery Problem Behind Moderna's Breakthrough | Örn Almarsson (3/4)
    The Delivery Problem Behind Moderna's Breakthrough | Örn Almarsson (3/4) 21.09.2026 29m
    The conversation covers layoffs, company transformation, patent cliffs, biotech's feast-and-famine cycles, modified mRNA, and the effort required to scale production from tiny academic batches to grams and kilograms.
  • Leaving Merck to Build a Biotech From Scratch | Örn Almarsson (2/4)
    Leaving Merck to Build a Biotech From Scratch | Örn Almarsson (2/4) 17.09.2026 30m
    At Merck, a three-month visa detour exposed Örn to another laboratory and reinforced the value of adaptability. He then describes leaving a secure role for Transform Pharmaceuticals, building a small team and collaborative culture, developing new formulation technologies, and helping create the patents and assets that led to a Johnson & Johnson acquisition.
  • How a Guitarist Became a Drug Delivery Pioneer | Örn Almarsson (1/4)
    How a Guitarist Became a Drug Delivery Pioneer | Örn Almarsson (1/4) 14.09.2026 25m
    He describes his first research opportunity at the University of Iceland, an early industry project in Copenhagen, and the mentors who pushed him toward bioorganic chemistry. The conversation follows his move to UC Santa Barbara, his work with Tom Bruice and Alex Klibanov, and the networking connection that led to Merck.

Popular in

The podcast also appears in the podcast charts of these countries.